Surufatinib achieves radiosensitivity in cholangiocarcinoma by suppressing GINS4 expression to induce Ca2+/cAMP signaling activation

doi:10.3748/wjg.121690

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 42

This Article

(3)

(0)

(27)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 14, 2026; 32(42): 121690
Published online Nov 14, 2026. doi: 10.3748/wjg.121690

Surufatinib achieves radiosensitivity in cholangiocarcinoma by suppressing GINS4 expression to induce Ca²⁺/cAMP signaling activation

Ai Huang, Yang Cao, Bin Li, Jun Xiao, Su-Dong Zhan, Ning-Yu Wang, Xiang-Ping Mei, Si-Zhe Zhao, Jun Han, Yong Xiao, Lin-Fang Wang, Hong Ma

Ai Huang, Ning-Yu Wang, Xiang-Ping Mei, Si-Zhe Zhao, Jun Han, Hong Ma, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China

Ai Huang, Ning-Yu Wang, Xiang-Ping Mei, Si-Zhe Zhao, Jun Han, Hong Ma, Hubei Key Laboratory of Precision Radiation Oncology, Hubei Key Laboratory of Precision Radiation Oncology, Wuhan 430022, Hubei Province, China

Ai Huang, Ning-Yu Wang, Xiang-Ping Mei, Si-Zhe Zhao, Jun Han, Hong Ma, Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China

Yang Cao, Jun Xiao, Su-Dong Zhan, Yong Xiao, Lin-Fang Wang, Department of Gastrointestinal Surgery, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China

Bin Li, Department of Anesthesiology, General Hospital of the Central Theater Command, Wuhan 430060, Hubei Province, China

Co-first authors: Ai Huang and Yang Cao.

Co-corresponding authors: Lin-Fang Wang and Hong Ma.

Author contributions: Huang A and Cao Y contributed equally to this study and they are co-first authors. Huang A, Cao Y, Li B, and Xiao J designed the study; Zhan SD, Wang NY, Mei XP, and Zhao SZ performed the experiments; Han J, Wang LF, Xiao Y, and Ma H analyzed the data; Wang LF and Ma H contributed equally to this work and serve as co-corresponding authors. and all authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

AI contribution statement: AI tools (specifically ChatGPT) were used solely for linguistic refinement and formatting assistance. No AI tool was involved in the generation of research data, interpretation of results, or formulation of conclusions. All AI-generated outputs were critically reviewed and revised by the authors.

Supported by China Health & Medical Development Foundation, No. chmdf2024-xrzx04-07; and Chinese Society of Clinical Oncology, No. Y-SY201901-0014.

Institutional animal care and use committee statement: This study was approved by the Medical Ethics Committee of Shanghai Gene Chem (Approval No. GSZE0346553), and the study followed the ethical guidelines of the Declaration of Helsinki.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Data sharing statement: No additional data are available.

Corresponding author: Hong Ma, Chief Physician, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 13 Hangkong Road, Wuhan 430022, Hubei Province, China. wudajianzhu2004@163.com

Received: April 1, 2026
Revised: May 15, 2026
Accepted: September 8, 2026
Published online: November 14, 2026
Processing time: 174 Days and 19.5 Hours

Core Tip

Core Tip: Surufatinib has been approved for the treatment of advanced cholangiocarcinoma. Our clinical trial demonstrates that surufatinib exerts prominent radiosensitizing effects. Its synergistic anti-tumor activity with radiotherapy is mainly achieved by suppressing the expression of GINS4, a critical proliferation-related gene, while simultaneously triggering the activation of Ca²⁺/cAMP signal cascades. Such molecular changes amplify radiation-triggered DNA injury, aggravate irreversible cellular damage, and ultimately facilitate robust apoptotic death of tumor cells upon radiation exposure. Our study provides more therapeutic options for clinical treatment.